BGI = Beijing Genomics Institute

;

BRCAm = BRCA mutation

;

CA-125 = cancer antigen 125

;

CR = complete response

;

eCRF = electronic case report form

;

FIGO = International Federation of Gynecology and Obstetrics

;

HRD = homologous recombination deficiency

;

HRRm = homologous recombination repair gene mutation

;

IDS = interval debulking surgery

;

N/A = not applicable

;

NACT = neoadjuvant chemotherapy

;

NED = no evidence of disease

;

PDS = primary debulking surgery

;

PFS = progression-free survival

;

PR = partial response

;

tBRCA = tumor BRCA

;

tBRCAm = tumor BRCA mutation

1. Global Cancer Observatory. Available at: https://gco.iarc.fr/
2. du Bois A, Reuss A, Pujade-Lauraine E, et al. Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234-1244. doi:10.1002/cncr.24149
3. da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, et al. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. Clinics (Sao Paulo). 2018;73(suppl 1):e450s. doi:10.6061/clinics/2018/e450s
4. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, et al. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5(11):1137-1154. doi:10.1158/2159-8290.CD-15-0714
5. Moore K, Colombo N, Scambia G, et al.  Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer [article and supplementary appendix]. N Engl J Med. 2018;379(26):2495-2505.
6. Banerjee S, Moore KN, Colombo N, et al.  Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1721-1731.
7. DiSilvestro P, Colombo N, Scambia G, et al. Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. J Clin Oncol. 2020;38(30):3528-3537. doi:10.1200/JCO.20.00799
8. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer [article and supplementary appendix]. N Engl J Med. 2019;381:2416-2428.
9. Ray-Coquard I, Pautier P, Pignata S, et al. Phase III PAOLA-1/ENGOT-ov25: maintenance olaparib with bevacizumab in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy and bevacizumab as standard of care [presentation]. Presented at: European Society for Medical Oncology (ESMO) Congress; September 27-October 1, 2019; Barcelona, Spain.
10. Harter P, Mouret-Reynier MA, Pignata S, et al. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Gynecol Oncol. 2022;164(2):254-264. doi:10.1016/j.ygyno.2021.12.016
11. González-Martín A, Pothuri B, Vergote I, et al.  Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391-2402.
12. Gonzalez-Martin A, et al.  Niraparib therapy in patients with newly diagnosed advanced ovarian cancer after chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 Study. Presented at: European Society of Gynaecological Oncology (ESGO); November 2-5, 2019; Athens, Greece.